What is the first treatment for acute myeloid leukaemia?

Acute myeloid leukaemia, or AML, develops when abnormal immature myeloid cells build up in the bone marrow. Induction treatment aims to clear these cells and allow healthy blood formation to recover. The regimen is selected after blood and bone-marrow testing, including tests that identify genetic features which may respond to a targeted medicine.

Treatment is often intensive and may require a hospital stay while blood counts are very low. Once a response is achieved, additional consolidation treatment is used to lower the chance of remaining disease. An allogeneic stem cell transplant may be discussed when the risk of relapse or the treatment response makes that approach appropriate; it is not the first treatment for every person.

Ask how long the initial admission may last and who to contact day or night. Arrange support for travel, childcare, work, and household tasks. Take prescribed preventive medicines exactly as directed, avoid sick contacts when advised, and do not take aspirin or supplements without checking first. Record temperature and symptoms according to the team’s instructions, and report changes rather than waiting for the next clinic visit.

Contact the AML team immediately for fever, chills, new cough, breathlessness, bleeding, black stools, severe headache, confusion, or marked weakness. Emergency assessment is needed for collapse, severe breathing difficulty, or bleeding that will not stop. Low blood counts during induction can make infection and bleeding urgent, so follow the written instructions from your hospital.

What do my bone-marrow and genetic tests show? Is targeted therapy part of induction? Will I need to stay in hospital, and for what warning signs should I call? How will response be measured? When might consolidation or an allogeneic stem cell transplant be considered?